2026 is here. Time flies, but not as fast as advances in artificial intelligence: if you blink, you will miss a new breakthrough or a new company emerging in the AI space. That is why we bring you AI trends in Pharma for 2026: what to expect. So you are not caught off guard, and you do not miss a thing. We have consulted our AI experts at Narrativa, and these are their predictions.

AI agents will dominate the conversation (what a surprise, right?)

As if they had not already dominated it enough in 2025, 2026 is shaping up to be the year of agentic AI. But what are AI agents and agentic AI? You may be wondering if you have been living under a rock all this time. Do not worry, at Narrativa we help you understand the concept:

An AI agent is a small software program that relies on the use of language models (GPT, Claude, Gemini, or other tools you use in your day to day work) to complete a VERY specific task.

Example: AI agent for the Efficacy section of the CSR

An AI agent for CSR can automatically generate the efficacy section of a Clinical Study Report. The agent checks that the numbers in the text match the tables and links each sentence to its source. The result is a draft ready for human review.

That is, the agent does NOT generate the CSR as a whole, but rather takes care of one part of the process. It is highly specialized: it does only one thing, but it does it very well.

Agents are changing the game right now. Language models have improved so much that they all now have reasoning capabilities, something DeepSeek impressed us with and that is now standard across the board.

Language models are already incredibly good, they hallucinate less, and prompts need to be less and less precise. This is fundamental for building good agents, which in turn are supported by functions.

For example, in Pharma, the function of checking the recommended dosage. The result will be the correct dosage based on the drug and the patient profile. If you ask the model, What is the dosage of amoxicillin for an adult with a respiratory infection?, the model calls the function in its response. The model does not solve it itself; what it solves is how to call the function. The model output is captured, the actual call to the database or clinical protocol is executed, and that value becomes the final answer.

What advantages do agents have?

Language models no longer give the direct answer, but rather how to obtain the answer. And what advantages do agents have over traditional software?

• Greater flexibility, with much less rigidity when it comes to programming.
• A much higher level of precision is achieved when a good agent system is in place, as hallucinations are reduced.

We recommend keeping a close eye on the progress of agents in 2026. Any task performed on a computer in the Pharma sector is susceptible to being automated with agents, saving vital time in Life Sciences.

Verticalization will be fundamental just to survive

Why is 2026 the year of verticalization? One of the problems with artificial intelligence systems is that there are solutions created by companies that work, but do not scale. What does this mean?

It means that these AI solutions work in small or controlled cases, such as pilots or one off projects, but cannot grow when complexity, data volume, number of clients, or operational requirements increase.

And in the pharmaceutical sector, where complexity could be considered synonymous with the industry itself, it is not possible to have a good solution if it is not scalable. When you need a human to perform certain actions, that is a bad sign.

So what do AI companies need in order to succeed in Pharma? To deeply understand the problems Life Sciences companies face, and therefore offer a verticalized solution.

A clear example is an AI solution that generates clinical texts from results tables. In a pilot, it may work well for a single study with constant expert supervision, but it becomes unviable when a pharmaceutical company needs to produce dozens of CSRs in parallel, with different protocols, SAPs, and regulatory requirements per market. At that point, if each document requires manual adjustments, reviews, and human corrections, the solution does not scale.

In Pharma, where processes are heavily regulated and variability across studies is high, AI is only useful if it is verticalized: it understands standards such as ICH, handles traceability, controls versions, and applies automatic validations. Without this deep domain knowledge, the technology may work, but it will not survive in large scale production.

Can you prove your value? ROI will be critical

Pharmaceutical companies no longer buy promises or endless pilots. In 2026, only solutions that demonstrate sustained economic and operational impact in production, at scale, will survive.

For many years, innovation in artificial intelligence remained at a more theoretical level. But Life Sciences companies no longer invest in AI for innovation’s sake; they invest for measurable and sustainable results in production.

ROI in AI is no longer measured only in isolated time savings, but in clear operational metrics:

• Reduced documentation cycles
• Less rework due to errors
• Decreased dependence on expert resources
• The ability to scale without linear cost increases

In Pharma, where delays in regulatory or clinical processes have a direct impact on time to market, these indicators are critical.

Solutions that show, through real data, that they can operate reliably in regulated environments, at scale, and with consistent quality are increasingly well positioned for success in 2026. If ROI depends on constant human intervention or manual configurations for each case, the return is diluted and the solution ceases to be viable at scale.

In summary…

In 2026, the conversation around artificial intelligence shifts away from technology itself and toward real business impact. AI agents, verticalization, and demonstrable ROI are not independent trends, but parts of the same shift: moving from solutions that impress in demos to systems that operate reliably in production.

In complex and regulated sectors such as Pharma, only platforms capable of scaling, integrating into critical processes, and generating sustained, measurable value will survive.